Last edition
News about "Merck neovascular AMD study"
Merck Initiates Phase 2b/3 Trial of MK-8748 for Neovascular Age-Related Macular Degeneration
Merck initiates a Phase 2b/3 trial of MK-8748 (Tiespectus), a bispecific antibody targeting Tie2 and VEGF pathways for treatment of neovascular age-related macular degeneration.
Merck Neovascular AMD Study | 04/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members